Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy

Clin Genitourin Cancer. 2013 Jun;11(2):85-8. doi: 10.1016/j.clgc.2012.09.003. Epub 2012 Oct 5.

Abstract

Background: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure.

Materials and methods: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition.

Results: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities.

Conclusions: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / surgery
  • Aged
  • Aged, 80 and over
  • Cryosurgery*
  • Gastrointestinal Tract / radiation effects
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / radiotherapy*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery
  • Radiotherapy Dosage
  • Radiotherapy, Conformal
  • Radiotherapy, Intensity-Modulated*
  • Treatment Failure
  • Treatment Outcome
  • Urogenital System / radiation effects

Substances

  • Prostate-Specific Antigen